LEO Pharma

LEO Pharma adds internationally recognized dermatologist to Global Leadership Team

Ballerup, March 14, 2023 – LEO Pharma today announced a split of its R&D organization into two distinct functions. To lead Research and Early Development, LEO Pharma has appointed Dr. Jacob Pontoppidan Thyssen as new Executive Vice President and Chief Scientific Officer. Jacob is an internationally recognized dermatologist and key opinion leader who will add his clinical experience and strong understanding of patients’ needs into LEO Pharma’s drug development.

LEO Pharma is fully committed to being a leader in medical dermatology by delivering an innovative dermatology portfolio for patients with unmet medical needs.

To achieve this goal, the company announced – in early 2023 - a significant shift in R&D to a research model, which aims at driving the early-stage pipeline with externally sourced innovation. Equally important for LEO Pharma is to maximize the value to patients of our three assets in late-stage development: tralokinumab, delgocitinib and IL-22R, ensuring competitive labels and the fastest possible approvals and launches to bring first- and best-in-class solutions to patients.

To support these two critical pillars, LEO Pharma today announced a split of its Research and Development organization into two distinct areas, both represented in the Global Leadership Team (GLT). The two GLT members - a Chief Scientific Officer and a Chief Development Officer – will both report to CEO Christophe Bourdon.

This means that as of May 1, 2023:

  • Dr. Jacob Pontoppidan Thyssen will join LEO Pharma to take over the responsibility for Research and Early Development in the role as EVP and Chief Scientific Officer.
  • Dr. Jörg Möller will, on an interim basis, take on the role as EVP and Chief Development Officer and continue to lead the Development organization.

Christophe Bourdon, CEO of LEO Pharma, comments

“This change is about ensuring coherence and focus from early to late-stage across the pipeline. We remain committed to the full development cycle and to a close collaboration between Research and Development. I am delighted to welcome Jacob to LEO Pharma and the Global Leadership Team and am confident that his experience will help spearhead our innovative portfolio. I am also very happy that Jörg has agreed to stay onboard in the interim. He can now fully focus on leading the Development organization and the activities of our clinical pipeline assets post proof-of-concept with an emphasis on the late-stage assets: tralokinumab, delgocitinib and IL-22R.”

Sharpening LEO Pharma’s external and competitive focus
Jacob Pontoppidan Thyssen is an internationally recognized dermatologist. He will remain affiliated with the University of Copenhagen, where he has served as a professor for many years, as well as with Bispebjerg Hospital, the largest Dermatology department in Denmark. His research has focused on inflammatory skin diseases, where he has paid particular attention to atopic dermatitis and chronic hand eczema, key focus areas of LEO Pharma. Jacob is a highly regarded member of several international societies and has published >600 peer reviewed articles.

Jacob Pontoppidan Thyssen comments:

“I am truly excited to join LEO Pharma. Medical dermatology is developing at a very fast pace and I see a great opportunity for LEO Pharma to positively impact patient care, now and in the future. This is a unique opportunity to fully leverage my clinical and research mindset to the company along with a personal network of top leaders in dermatology for the benefit of patients affected by skin diseases.”

Jörg Möller:

”LEO Pharma is on an exciting transformation journey and maximizing the opportunities in our late-stage pipeline will be a major focus for the organization. In this context, I continue to support the transition to the adjusted R&D strategy which we announced in January this year on an interim basis with a focus on our clinical pipeline assets post proof-of-concept, especially tralokinumab, delgocitinib and IL-22R.”

With the changes announced today, Thorsten Thormann, currently VP Research and Early Development, is leaving LEO Pharma. During the transition, Thorsten will work with Jacob to ensure a smooth handover.

Thorsten has been with LEO Pharma for almost 20 years. He has been instrumental in driving LEO Pharma’s Research & Early Development forward, and most recently, in developing the adjusted R&D strategy.

Christophe Bourdon:

“I would like to thank Thorsten for everything he has has done for LEO Pharma in Research and Early development for the past years. We are in a good place today because of his curiosity, dedication and support. Thorsten has also played a key role in bringing assets such as delgocitinib and IL-22R to LEO Pharma. I sincerely wish him all the best of success in his next endeavor.”


Media contact:
Henrik Heskjær, hdtdk@leo-pharma.com, +45 3140 6180

About LEO Pharma

LEO Pharma
LEO Pharma
Industriparken 55
2750 Ballerup

4494 5888http://www.leo-pharma.com/

About LEO Pharma

LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 4,700 people, serving millions of patients across the world. In 2022, the company generated net sales of DKK 10.6 billion. Learn more at www.leo-pharma.com.

Subscribe to releases from LEO Pharma

Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from LEO Pharma

LEO Pharma announces topline results of phase 3 trial in China for Enstilar® (LEO 90100) demonstrating superiority in adult Chinese subjects with stable plaque psoriasis7.5.2024 20:00:00 CEST | Pressemeddelelse

Enstilar® (LEO 90100) showed superiority over Daivobet® ointment in primary and both secondary endpoints in the testing hierarchy showing improved efficacy in reducing the severity and extent of stable plaque psoriasis. Overall, both Daivobet ointment and Enstilar – each of them LEO Pharma products – were well tolerated. Safety profiles were consistent with previous trial findings and as expected with no new safety concerns identified. The trial is a commitment of LEO Pharma’s expanding presence in China, making a fundamental difference for Chinese patients living with psoriasis through additional treatment options. Enstilar – a unique cutaneous foam formulation built on the active ingredients of Daivobet – is a global market leader in topical psoriasis.

Solid start to the year: 13% revenue growth driven by strong performance in dermatology3.5.2024 09:00:00 CEST | Pressemeddelelse

Q1 2024 Trading Update (Unaudited): In Q1 2024, LEO Pharma delivered a revenue growth of 13% in constant exchange rates (CER). The dermatology portfolio saw accelerated growth in revenue of 16%. The acquisition of TMB-001 to the treatment of congenital ichthyosis added a late-stage asset to LEO Pharma’s medical dermatology pipeline, and delgocitinib for chronic hand eczema (CHE) is on track for its planned European launch in Q4 2024. Full-year outlook has been revised slightly upwards.

LEO Pharma announces positive phase 3 head-to-head data results from DELTA FORCE trial comparing delgocitinib cream with alitretinoin capsules in adults with severe chronic hand eczema (CHE)24.1.2024 08:00:00 CET | Pressemeddelelse

Delgocitinib cream demonstrated a superior reduction in Hand Eczema Severity Index (HECSI) score from baseline to Week 12 compared to alitretinoin capsules as its primary outcome measure. Delgocitinib cream also demonstrated superiority to alitretinoin capsules in all key secondary outcome measures, including Investigator’s Global Assessment (IGA)-CHE treatment success, health-related quality of life (HRQoL), and a lower number of treatment-emergent adverse events. DELTA FORCE is the first head-to-head phase 3 trial comparing a systemic and topical treatment for CHE.1 With only one treatment option currently approved for severe CHE and no approved optionsfor more moderate forms of the disease, there is a considerable unmet need for patients living with CHE.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye